About the Technology Transfer Office
The CU Technology Transfer Office pursues, protects, packages, and licenses to business the intellectual property generated from research at CU. The TTO provides assistance to faculty, staff, and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU, visit www.cu.edu/techtransfer.
$4 million in royalties and 11 startups 1065_ 8/22/11 - We're here to check on the temperature at the CU Tech Transfer Office with Dave Allen, Associate Vice President of Technology Transfer at the University of Colorado. We check in with Dave every year to get a sense of what their fiscal year was like. This year? "We had a solid year!" said Dave, "For us the emphasis is inventions and faculty - we had 250 inventions and that's good." About 60% of these are [bio medical] related and then the other 30% being spread out across energy and chemical materials, software outfits, electronics, those kinds of things. In the bio most of what we get are in the therapeutics really. So we have a lot of good technology to work with. We see about a thousand inventions a year and our job is to figure out what in those are patentable, feasible and commercially viable and last year we filed almost the same number of patent applications as the year before. The core of our realm is exclusive licenses - those are assets that people can build on and develop. We had 37 last year and that's comparable to other years. It's not a big secret here, the technology economy has been in the doldrums for a couple of years. And we're glad that we can put 37 technologies exclusively in the hands of companies - and the vast majority of those are Colorado companies. Another thing people are interested in are startups - we've had eleven and that tracks, last year we had nine. The other thing to raise is our royalty income - last year we had $4 million in royalties. So it's been a solid year. We are looking forward to better. And one of the things we are doing that's different, and I think a lot of people will be interested in this. I don't believe there's anyone else in the country doing this. We're starting a program called the Technologies Transfer Office Fellows program. It's a trial this year. If it works we're going to scale it up. We'll extend our reach beyond by multiplying the numbers of bright, motivated people who want to add importance to their career. It is a bold plan with great promise! There's much more.... Related Links: CU Technology Transfer Office || CU TTO Channel || TTO Blog || CU TTO Awards || Award Photos || Keywords: CU Tech Transfer Office with David Allen, University of Colorado,
Inventions, Energy, Chemical Materials, Software Outfits, Electronics, Bio Medical, Fellows Program, 8/22/11 - bytes=11280199 LISTEN to David Allen, Associate Vice President, Technology Transfer Office at CU
About the University of Colorado The University of Colorado is a premier teaching and research university with four campuses: the University of Colorado at Boulder, the University of Colorado at Colorado Springs, the University of Colorado Denver and the University of Colorado Anschutz Medical Campus. Nearly 57,000 undergraduate and graduate students are pursuing academic degrees on CU campuses. CU is ranked seventh among public institutions in federal research expenditures in engineering and science by the National Science Foundation. Academic prestige is marked by the university’s four Nobel laureates, seven MacArthur “genius” Fellows, 18 alumni astronauts and 19 Rhodes Scholars. For more information, go to www.cu.edu.
CU Announces Annual Technology Transfer Awards
Researchers working on biofuels, cancer treatments and addiction support among those honored for technology commercialization.
DENVER (Jan. 18, 2011) – The University of Colorado Technology Transfer Office hosted its annual awards ceremony, honoring six faculty researchers, two companies founded on university research, and several members of the local entrepreneurial community.
Over the past two decades, CU researchers have developed technologies that have led to the creation of 103 new companies. Of these, 79 have operations in Colorado, seven have “gone public,” becoming publicly traded companies (either through an IPO or via a reverse merger), and 12 have been acquired by public companies. Companies created based on CU technology have attracted a total of over $4 billion in financing.
“CU plays a big part in the economy of Colorado and the lives of Colorado’s citizens, and technology transfer – the process of conveying university research inventions to companies – is one dimension of that impact,” said David Allen, associate vice president for technology transfer at CU. “Most of the companies that license CU technology operate in Colorado. This event recognizes excellence in the people and licensee companies that are part of the CU technology transfer environment.”
Faculty and companies recognized this year represent all CU campuses, and are developing technologies ranging from biofuels and hybrid aircraft engines to novel treatments for cancer, heart disease and eye disease. This year’s award winners include:
Ryan T. Gill, Inventor of the Year, Boulder. Gill, an associate professor of chemical and biological engineering, is developing new tools and applications for directed evolution of genomes. In particular, his work focuses on metabolic engineering for sustainable bio-diesel and bio-gasoline production. Technology from the Gill lab has formed the basis of OPX Biotechnologies, a venture-backed Boulder company making renewable bio-based chemicals and fuels that are lower cost, higher return and more sustainable than existing petroleum-based products.
Malik Y. Kahook and Naresh Mandava; Inventors of the Year, Anschutz Medical Campus. Kahook, an associate professor of ophthalmology, and Mandava, chair of ophthalmology, work on novel treatment for eye diseases including glaucoma, macular degeneration, and retinal detachment. (Listen: Interview 5/2/11)
Jean N. Koster, New Inventor of the Year, Boulder. A professor of aerospace engineering, Koster has done work expanding the concepts of hybrid vehicles to airplanes; his team’s research is the foundation of a new company, Tigon EnerTec.
Dan Theodorescu; New Inventor of the Year, Anschutz Medical Campus. Theodorescu, director of the University of Colorado Cancer Center, has demonstrated efficacy of a new class of drugs in the treatment or bladder, prostate and lung cancer and successfully formed a collaboration team to pursue new compounds to take into clinical trials.
Rory A. Lewis; New Inventor of the Year, Colorado Springs. An assistant professor of computer sciences, Lewis developed a social medial platform for addiction recovery that is now optioned to Syberenety, Inc., a Colorado Springs startup company which won a Phase I SBIR award to develop the technology.
miRagen Therapeutics; Bioscience Company of the Year. miRagen Therapeutics (based in Boulder, Colo.) is a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease. miRagen has raised $12M in capital from several top-tier venture firms.
Sundrop Fuels; Physical Sciences/Engineering/IT Company of the Year. Sundrop Fuels (based in Louisville, Colo.) is a solar gasification-based renewable energy company developing a technology to turn any type of plant material into ultra-clean, affordable liquid transportation fuel for use in today’s automobiles, diesel engines and aircraft. In September 2009, Sundrop began operations at an 80 kW (thermal) solar research facility in Broomfield; the company plans to build a full-scale commercial plant capable of producing 100 million gallons of fuel a year by 2015.
Lauren C. Constantini; Business Advisor of the Year. Constantini has over 15 years of experience in pharmaceutical development and is a recognized leader in the area of central nervous system (CNS); she is a frequent participant in review and strategy sessions used to move forward development of CU technologies and start-up companies. (LISTEN Interview 2/11/11)
Mikhail “Misha” Plam; Serial University Startup Entrepreneur Award. Plam has built a distinguished career on successfully bringing university innovations to market. He has founded three companies based on inventions from the University of Colorado: AmideBio, BiOptix Inc. and Sievers Instruments (acquired by GE).
James C. T. Linfield; Colorado Technology Infrastructure Leadership Award. Linfield is a partner in the Cooley LLP Business department and Partner-in-Charge of their Colorado office; he serves on the advisory boards of numerous CU entrepreneurship and innovation initiatives, and is among the leaders promoting new initiatives and collaboration strategies in Colorado.
Pricing for renewable energy technologies is changing 1068_ 8/22/11 - Larry interviewed Paul Komor, Education Director of CU’s Energy Institute, University of Colorado at Boulder. Paul is a member of the graduate faculty at the University of Colorado, Boulder. He currently teaches in the Environmental Studies program and is the Education Director of the University’s Renewable and Sustainable Energy Institute (RASEI). The rapid growth of renewable energy is a bright spot in a troubled economy. Clean energy companies are expanding, especially in Colorado, and federal stimulus funds are flooding into the industry. Now is the time to identify attractive opportunities in this rapidly evolving industry. Get ahead of the curve—take an intensive, four-day executive education certificate program offered by the Deming Center for Entrepreneurship at CU-Boulder that provides an in-depth look at renewable energy technologies and policies. Upon the completion of the certificate program, participants will be able to answer: Which renewable energy technologies have the greatest short- and long-term promise? How are costs and pricing for renewable energy technologies changing? How do federal and state policies affect the growth of different technologies? What are the key challenges of to the growth and success of renewable energy and how can they be overcome? How can I identify business, commercial, and job opportunities with renewable energy? Participants may take all four courses to earn a RETool Renewable Energy Certificate, or may take courses individually. The RETool instructors teach and research the evolution of renewable energy, and are frequently invited to serve as guest speakers for industry and other groups. Both faculty members are active in the Renewable and Sustainable Energy Institute (RASEI), a new joint institute between the National Renewable Energy Laboratory and the University of Colorado at Boulder. Related Links: RETool Overview || CU Technology Transfer Office || Leeds – Deming Center for Entrepreneurship || CU TTO Channel || Business Podcasting || Keywords: Paul Komor, Deming Center for Entrepreneurship, Renewable and Sustainable
Energy Institute, RETool, RASEI, Energy Institute, University of Colorado at Boulder, 8/22/11 bytes=7047526
LISTEN to Paul Komor, Education Director, Retool Program, Leeds School of Business
CU Technology Transfer, the Challenges and the Choices
Annual Report 2009-2010
905_ 10/4/10- "Over the last seven years we've (generated) 69 companies, and those are Colorado companies, 57 are still around. Last year was though, we lost a couple companies. It's been brutal. Very tough for early stage technology companies. I see the sun shining through the darker clouds of the innovation economy recession." said David Allen, Associate Vice President for Technology Transfer at the University of Colorado. Larry discussed with David the University of Colorado Tech Transfer (TTO) annual report for 2009 - 2010. While there are many challenges, there are a number of very positive aspects. Here's an overview of the TTO Dashboard:
~ invention disclosures (respectable year with continued pipeline growth)
+ US patent applications (solid year for both TTO and licensee companies)
+ exclusive deals (good year, especially given the soft economy)
-nonexclusive deals (most such deals due to one software program)
~ start-ups (slightly down, but continued high level performance)
~ POC program (strong projects primarily supported by State BDEG)
-overall revenue (expected low revenue, worsened by recession)
-liquidations (sitting on ownership interests in 55 companies)
+ financial reserve (recovery of TTO’s Long-Term Investment account)
-patent reimbursements (shortfall compared to previous years)
-start-up and early-stage licensee financings (very difficult market)
+ support from the business community (continued strong engagement)
+ support from the CU Administration (strategic importance maintained)
+ TTO personnel (capable TTO staff and collaborative team environment)
+ Net, Net TTO had another solid year except for low licensing revenue
In addition here are the TTO stats for IP and Licensing Portfolio at a Glance (as of 07/01/2010): Total U.S. Patents in force : 306 - Total U.S. Patents in prosecution: 309 - Exclusive Licenses in good standing: 153 - Non-Exclusive Licenses in good standing: 209 - Bio Licenses in good standing: 176 - Non-Bio Licenses in good standing: 184.
At the BioWest Conference, CU TTO team was a winner of the 'Business Partner of the Year Award'. Click on the link for a complete report...
Tech Transfer Award Winners and Bio Frontiers Institute
1104_ 11/7/11 -
We took a trip out to Broomfield, to meet Dave Allen, Associate VP, Tech Transfer Office, University of Colorado, where he introduced us to Jim Linfield, Managing Partner at Cooley. Jim was the recipient of the Colorado Technology Infrastructure Leadership Award 2011. Really, if you spend time around the university or in the bio or clean tech communities, you know Jim - but there's more to the story. Dave Allen said the best way he could describe the award "...is acknowledgement that Jim has his fingerprints on all the things that work really well as it relates to the technology environment/infrastructure/ecosystem creating a vibrant environment for commercialization of technology..." He goes way beyond, whether it's bio science, cleantech, Boulder Innovation Center, Deming Center for Entrepreneurship, Technology Transfer Advisory Board, and more. I don't think they'd be what they are without Jim, so that was basically the acknowledgement." Dave points out that Jim plays a major role in two other significant areas. He played an instrumental role in the attraction of Tom Cech back to the university about two, three years ago. He's one of the leaders in the Bio Frontiers Advisory Board and he is one of the three people on the FRA Board at Anschutz Medical Campus - both provide interesting challenges and great opportunities. Larry asked Jim for what was on the horizon. In the Bio Science area there is the Bio Frontiers Institute which will be the center of activity for the university interdisciplinary studies and Tom Cech is the head of that, the building should be completed in February on the east campus in Boulder. Jim said, "I think that will solidify CU's position as one of the leading institutions for interdisciplinary research in the life sciences area, covering both therapeutics and diagnostics but also bio fuels, so I think it will be a remarkable institution." ...Listen for much more... Related Links:
Cooley LLP ||
CU Technology Transfer Office ||
CU TTO Channel ||
TTO Blog ||
CU TTO Awards ||
Award Photos ||
Keywords: Jim Linfield, Cooley, David Allen, CU Technology Transfer Office, CU TTO,
Bio Frontiers Institute, Bio Science, Cleantech, Boulder Innovation Center, Deming Center for Entrepreneurship, Fitzsimmons
Redevelopment Authority Listen to: Jim Linfield, Managing Partner, Cooley and Dave Allen, Associate VP, Tech Transfer Office, University of Colorado
Inventors of the Year, Anschutz Medical Campus
1008_ 5/2/11 -
We are here at Rocky Mountain Lyons Eye Institute to talk with Dr. Malik Kahook, an associate professor of ophthalmology, and Naresh Mandava M.D., Professor and Chair of the Department of Ophthalmology, Inventors of the Year, Anschutz Medical Campus awarded by the University Colorado Tech Transfer Office. Malik said, "The award that we received recently centered around work that we are doing jointly using a base polymer for devices that are surgically implanted or injected into the eye to either induce changes that would improve a disease process or introduce medications into the eye that would treat the disease process over time. So a depot of medication, if you will, using a polymer based system." Naresh pointed out, "The exciting thing about the technology is that it's applicable to so many diseases such as glaucoma, macular degeneration, potentially even common things like cataracts. So we're very excited that these polymers that haven't had a place in ophthalmology will have place in treating these troubling diseases. They also have an active collaboration with members in the Department of Bio Engineering. Larry asked, "What advice would you give to researchers and scientists in this coming year or two? Malik, "Growing up, I always got the advice from my mother; In order to be successful you've got to surround yourself with good people. The idea for research, being the baby of the clinicians and scientists is something we should look after with similar advice - Surround your idea with good people. So the No. 1 advice I'd like to offer is, Surround any idea with the right team members and that's going to guarantee success." Naresh, "My advice is along the same lines. I think collaboration is key. I think being passionate about what you're researching is key. Malik and I are fortunate in what we do is taking care of patients every day, we know where the holes are in terms of traditional modalities of treatment we have for diseases like glaucoma and macular degeneration and really we are very passionate about what we do. You have to be driven, have a goal in mind and don't be afraid to fail." Listen, there's much more.....
Malik Kahook ||
Naresh Mandava ||
CU Technology Transfer Office ||
CU TTO Channel ||
TTO Blog ||
CU TTO Awards ||
Award Photos ||
Rocky Mountain Lions Eye Institute ||
Keywords: Malik Kahook, Naresh Mandava, CU Technology Transfer Office,
Colorado, Glaucoma, Researcher, Ophthalmology, Anschutz Medical Campus, Blinding Disease, Rocky Mountain Lions Eye Institute
5/2/11 bytes=7702468 LISTEN to
Dr. Naresh Mandava and Dr. Malik Kahook, Inventors of the Year
Business community helping with technology maturation 969_ 2/14/11 - The University Colorado Tech Transfer Office (TTO) works with academics at the university who are interested in bringing their technology out into the world of potential licensing to pharmaceutical companies or other types of companies. TTO has done a spectacular job of helping identify the technologies within the university that are important. They protect it with patents and then help these groups with marketing and licensing the technologies out. Larry interviewed Lauren Costantini, who has been honored as the University of Colorado Tech Transfer Office, Business Advisor of the Year. Dr. Costantini has over 15 years of experience in pharmaceutical development and is a recognized leader in the area of central nervous system (CNS). She has led preclinical development, early and pivotal international clinical trials, and regulatory affairs, and has played a key role in business development activities including licensing, patents, due diligence, and partnering discussions. She was previously on faculty at Harvard Medical School where she investigated mechanisms and treatments for neurodegeneration. For the last two years Dr. Costantini has been a consultant and advisor to TTO and has counseled faculty and TTO on business planning, etc. She has also been involved in advising several biomedical startups from the University of Colorado. Lauren explained, "TTO works with academics at the university who are interested in bringing their technology out into the world of potential licensing to their pharmaceutical companies or other types of companies. TTO has done a spectacular job of helping identify the technologies within the university that are important. They protect it with patents and then help these groups with marketing and licensing the technologies out. Helping those technologies mature is not just taking something from the bench and telling those investigators what may help move them through, but also connecting those investigators with people in the VC world or even the pharmaceutical world, or key opinion leaders."...listen now... Related Links: CU Technology Transfer Office || Lauren C. Costantini, LCC Consulting || CU TTO Channel || TTO Blog || CU TTO Awards || Award Photos || Keywords: Lauren C. Costantini, LCC Consulting, CU Technology Transfer Office, Clinical
Trials, Regulatory Affairs, business development activities including licensing, patents, Due Diligence, Partnering Discussions >
2/14/11 bytes=6913361 LISTEN to Lauren Costantini, CU TTO "Business Advisor of the Year"
Keep at it, eventually there will be a turn around
960_ 1/31/11 -
ARCA Biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. Larry interviewed Michael R. Bristow, MD, Ph.D. CEO & Chief Science and Medical Officer of ARCA at the CU Technology Transfer Office Awards banquet. Dr. Bristow has been a favorite interview for w3w3® for years. Larry asked him, "Michael what are the biggest changes you've seen in this last year in your industry?" He replied, "It's been a couple of tough years, but I think things are starting to turn around and basically the atmospherics have gotten a lot better. Just coming off a JP Morgan meeting, it was, I thought, a completely different tone this year." Dr. Bristow had some interesting insights about funding. "Well, it's sort of like financing of real estate was back in the early 80s when interest rates were 20% - you've got to do creative financing. So, all kinds of vehicles have been used through this period. ARCA biopharma, for instance did a reverse merger, bought a company that was NASDAQ listed, that had a bunch of cash - that proved to be a good move. So people have gotten through this one way or another. But we need to get back to traditional sources of funding." Larry asked, "Is there any particular advice to people in your arena?" Spoken like a true leader he replied, "Yes, don't give up. I mean, tenacity, keep at it, eventually there will be a turn around. Now, when things aren't going too well, may be the best opportunity there is in terms of acquiring assets. Think ahead. Think positive." Dr. Bristow joined ARCA as one of ARCA’s founders in September 2004, and has served as Chairman and Chief Science and Medical Officer of ARCA until he was appointed to his current position of Chief Executive Officer in July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc.
ARCA biopharma ||
CU Technology Transfer Office ||
CU TTO Channel ||
TTO Blog ||
CU TTO Awards ||
Award Photos ||
Keywords: Michael Bristow, ARCA biopharma, CU Technology Transfer Office, Biotech,
Cardiology at the University of Colorado Health Sciences Center, University of Colorado Cardiovascular Institute 01/31/11 bytes=2927702
Michael R. Bristow, MD, Ph.D. CEO & Chief Science and Medical Officer of ARCA
We have actually had a big year 957_ 1/24/11 - Larry interviewed Dr. Timothy Rodell, the President and CEO of GlobeImmune at the CU Technology Transfer Awards banquet. Larry asked, "It's been over a year since we last interviewed, what's happened during that time?" Dr. Rodell replied, "We've actually had a big year. We completed a large, mid-stage trial in Hepatitis-C patients. To remind you, what we're doing is to use genetically engineered yeast to stimulate the immune system so that it recognizes foreign invaders, and those can be either infectious agents or cancer, it recognizes them and fights against them. What we've now shown in Hepatitis-C is by using our products (called tarmagens) to augment the response, we can actually increase by 25% on a relative basis, the percentage of patients that are cured. So this was a big year for us because I actually could stand up in front of the company, for the very first time and say, "what you've been doing for the last seven years is going to result in people being alive 20 years from now who ultimately would have died of their disease. So that's a really exciting thing. What we're doing now is getting ready for the final stage of trials, called pivotal trials, that could lead to approval and open up commercialization. We hope to start those trials, perhaps by end of 2011. They will run for about two years after that. This is a very challenging time for financing small companies and 2010 was an improvement over 2009 and a major improvement over 2008. But we still have a long way in front of us. So what 2011 is about for us is getting ready to run those pivotal trials in Hepatitis-C and figuring out how we're going to finance those trials..." There's much more, listen now... Related Links:
CU Technology Transfer Office ||
CU TTO Channel ||
TTO Blog ||
CU TTO Awards ||
Award Event Photos ||
Keywords: Dr. Timothy Rodell, CU Boulder, Technology Transfer Office, Hepatitis-C, Pancreas Cancer, Human Clinical Trials > 01/24/11 bytes=3650354 LISTEN to Dr. Timothy Rodell, GlobeImmune at the Tech Transfer Awards
Funding was a big part of the program 954_ 1/24/11 - Funding was a big topic at the CU Technology TransferAwards banquet. Larry interviewed Dick Hinson who is the senior vice president of the Aurora Economic Development Council. Larry asked, "What's your view on funding today?" Dick replied, "Tonight they've been talking about venture funds and creating a fund of funds in Colorado, to help fund new startups, things like that, moving along the path of 'proof of concept'. I think this is critical because that is the stumbling block for a lot of business development over the past couple of years. You know, the liquidity freeze, the banks haven't been making loans, so it is very very critical that these funds are made available so businesses can expand, do research in areas and the commercialization of what they're trying to do. Larry asked, "Aurora is a very active participant in the business community. Is there anything you're doing in this area as it relates to funding?" Dick replied, "Right now we see a lot of development across the Fitzsimmons/Anschutz Campus that's starting to occur because a developer (Corporex) came along bringing their own funding. They were able to do their own projects and then they had some local help. But that's the critical thing. If we can get the funding, there are a lot of projects ready to go. We've seen this in the Colfax corridor, projects that are ready to go but have been stopped in their tracks for the lack of funding. Over the past couple of years we've seen that same sort of venture capital sort of dry up in Colorado. Hopefully, and from what we've heard here tonight, maybe this is loosening up a little. Once that happens a lot of businesses are going to be able to take advantage of it." Listen now... Related Links: Aurora Economic Development Council || Colorado Business Loan Funds || CU Technology Transfer Office || CU TTO Channel || TTO Blog || CU TTO Awards || Award Photos || Keywords:Dick Hinson, Aurora Economic Development Council, Funding, Venture Capital,
CU Boulder, Technology Transfer Office, Fitzsimmons/Anschutz Campus, Fund of Funds 01/24/11 bytes=2607128 >
Listen To: Dick Hinson, Sr. VP Aurora Economic Dev Council
831_ 4/26/10 -
TTO New Inventor - Preventing Blindness Malik Kahook, New Inventor of the Year UC Denver named by by the Technology Transfer Office was interviewed by Larry. Dr. Kahook explained, "The invention award was given to us for a non-invasive device that treats Glaucoma. Glaucoma is a disease that involves high eye pressure in the eye, along with other different things that can lead to disease of the optic nerve. With glaucoma, that optic nerve slowly dies. There are three ways of treating this involving medication, laser or surgery, but each has limitations. About ten years ago at the end of my medical school training, I started thinking of different ways we could approach glaucoma therapy without the need for one of those three different approaches, and started doing this work as a resident here at the University of Colorado. The approach was a very systematic study that started looking at preclinical work; eventually moving to preclinical studies; looking at this device and eventually taking it into humans here in the next few weeks. Larry asked, "How do you actually work with the CU Tech Transfer Office?" "TTO was instrumental in moving this project forward. I have to admit that initially I did not know much about tech transfer. As a physician and a researcher, my focus really is on how do I get this device to work, how do I actually get this to show the benefit that would actually make me want to move it forward in further studies. And the last thing on the mind is really, how do I deal with tech transfer, how do I worry about intellectual property?" He shares many other ideas... Related Links: Malik Kahook || CU Technology Transfer Office || CU TTO Channel || Rocky Mountain Lions Eye Institute ||
Keywords: Malik Kahook, CU Technology Transfer Office, Colorado, Glaucoma, Researcher, Blinding Disease, Rocky Mountain Lions Eye Institute > 4/26/10 Chnl: News bytes: 6783689 Listen to Malik Kahook , Physician and Researcher, UC Denver New Inventor of the Year!